This trial is testing a new combination treatment for patients with untreated renal cell carcinoma. The usual treatment is immunotherapy with ipilimumab and nivolumab, followed by nivolumab alone. The new treatment adds cabozantinib to nivolumab after initial treatment with ipilimumab and nivolumab. It is not yet known if this new combination treatment is better than the usual treatment.
1 Primary · 5 Secondary · Reporting Duration: Up to 5 years
1046 Total Participants · 2 Treatment Groups
Primary Treatment: Ipilimumab · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: